news-15112024-040106

SolasCure Ltd, a biotechnology company, is teaming up with the U.S. Army Institute of Surgical Research (USAISR) to work on improving combat wound care. The collaboration will focus on evaluating SolasCure’s Aurase Wound Gel, a product designed to help manage combat wounds by promoting wound healing through debridement and preparation of the wound bed.

The partnership will involve two non-clinical development projects aimed at assessing the effectiveness of Aurase Wound Gel in reducing wound biofilm production and bioburden in prolonged field care scenarios. These projects will specifically target combat-relevant strains of bacteria such as Pseudomonas aeruginosa and MRSA, which are known to complicate wound care and lead to chronic infections.

The USAISR is known for its cutting-edge research in improving the care of combat casualties, making it an ideal partner for SolasCure in this endeavor. The goal of the collaboration is to gather non-clinical data that could potentially validate the use of Aurase Wound Gel in challenging combat conditions.

Lee Harle, the Chief Executive Officer of SolasCure, expressed his excitement about the collaboration with the U.S. military and the opportunity to further develop their technology for combat wound care. He looks forward to the results of the projects and the potential impact of Aurase Wound Gel in managing biofilm and bioburden in combat situations.

This collaboration highlights the importance of innovation and research in the field of healthcare, particularly in addressing the unique challenges faced in combat settings. By leveraging the expertise of both SolasCure and the USAISR, there is a great opportunity to advance the treatment of combat wounds and improve outcomes for military personnel in the field.

Overall, this partnership represents a significant step forward in the field of wound care and demonstrates the value of collaboration between different sectors to tackle complex healthcare challenges. The dedication and commitment of both SolasCure and the USAISR to improving combat wound care are commendable, and the outcomes of their research projects are eagerly anticipated.